XIBER Science GmbH 
Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent organ failure. Xiber will enter market by two niche indications: Acute Lung Injury & Primary Graft Dysfunction after Lung Transplantation – with a total market volume of 630 Mio. USD.
In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start in the beginning of 2016.
Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders. The University holds a non-controlling interest and rewards its shares by providing cooperation, infrastructure, facility services and management support.
To drive its developmental program till the completion of a phase I trial Xiber needs ~ 4 Mio €. This is largely covered by Austrian funds and loans. For the remaining Xiber seeks 2 Mio € equity from VC partner. Xiber has already signed a LOI with an established VC company.
